Welcome to our dedicated page for Integra Lifesciences Hldgs Cp news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra Lifesciences Hldgs Cp stock.
Integra LifeSciences Holdings Corporation reports developments as a global medical technology company focused on neurosurgery and tissue reconstruction. News commonly covers quarterly financial results, revenue guidance, operational execution, supply reliability, quality-management work and product availability across its medical technology portfolio.
Company updates also include clinical evidence and medical-conference activity for wound reconstruction products such as PriMatrix Dermal Scaffold, Integra Dermal Matrices, Cytal Wound Matrix, MicroMatrix and AmnioExcel. Recurring corporate topics include leadership appointments, investor conference presentations, manufacturing progress and segment activity within Codman Specialty Surgical and Tissue Technologies.
Integra LifeSciences (IART) has announced a leadership change, promoting Michael McBreen to executive vice president and president of Codman Specialty Surgical, effective June 8, 2020. McBreen replaces Dan Reuvers, who is leaving to become CEO of Tactile Systems Technology. McBreen has a strong background with Codman Neurosurgery, having joined Integra through its acquisition from Johnson & Johnson in 2017. Peter Arduini, CEO, praised McBreen's leadership while acknowledging Reuvers' contributions to the company's success in neurosurgery.
Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced its participation in two investor conferences in May 2020. Glenn Coleman, COO, will present at the BofA Securities Virtual Health Care Conference on May 12 at 11:40 am ET. Carrie Anderson, CFO, will present at the UBS Virtual Global Healthcare Conference on May 20, also at 11:40 am ET, with a webcast available on the company’s investor relations site. The company is a leader in regenerative technologies and emphasizes its commitment to providing high-quality solutions for healthcare professionals.
Integra LifeSciences reported Q1 2020 revenues of $354.3 million, down (1.5)% year-over-year, attributed to COVID-19 impacts. GAAP earnings per diluted share fell to $0.11 from $0.38 in Q1 2019. Adjusted earnings were $0.48, compared to $0.65 previously. The company estimates a revenue hit of $20-$25 million due to deferred surgical procedures. Gross margin decreased to 62.3%, and adjusted EBITDA was $75.7 million. Full-year guidance remains withdrawn due to uncertainties from the pandemic.